Varenicline vs Nicotine Patch for Quitting Smoking
Author Information
Author(s): H-J Aubin, A Bobak, J R Britton, C Oncken, C B Billing Jr, J Gong, K E Williams, K R Reeves
Primary Institution: Hôpital Emile Roux, Assistance Publique-Hopitaux de Paris, France
Hypothesis
Does varenicline provide a higher smoking cessation rate compared to transdermal nicotine replacement therapy?
Conclusion
Varenicline resulted in higher smoking abstinence rates and reduced cravings compared to transdermal nicotine replacement therapy.
Supporting Evidence
- Varenicline showed a continuous abstinence rate of 55.9% compared to 43.2% for NRT.
- Varenicline significantly reduced cravings and withdrawal symptoms compared to NRT.
- The most common side effect of varenicline was nausea, reported by 37.2% of participants.
Takeaway
This study found that a new medicine called varenicline helps people stop smoking better than a nicotine patch.
Methodology
A 52-week, open-label, randomised, multicentre, phase 3 trial comparing varenicline and transdermal nicotine replacement therapy.
Potential Biases
Differential dropout rates may have influenced the results.
Limitations
The open-label design may have introduced bias, and the treatment durations were different.
Participant Demographics
Participants were smokers aged 18-75, with a mean age of 42.9 years, and included both males and females.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 1.26 to 2.28
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website